Mode
Text Size
Log in / Sign up
Phase 1 N=46 Other

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

Healthy

Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
diacerein 1% ointment (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Castle Creek Pharmaceuticals, LLC
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Skin Irritation Score
0; 0; 339; 15 <0.0001 sig

Summary

Single center, randomized, controlled, evaluator blinded, within-subject study to evaluate the irritation potential of diacerein1% ointment on normal skin of healthy volunteers, using a cumulative irritancy patch test (CIPT) procedure.

Eligibility Criteria

Key Inclusion Criteria

  • Is a healthy male or female (to be confirmed by medical history);
  • Is 18 years of age or older;
  • In the case of a female of childbearing potential, is using two acceptable forms of birth control;
  • In the case of a female of childbearing potential, has a negative urine pregnancy test (UPT) on Day 1 prior to randomization and are willing to submit to a UPT at the end of study (EOS);
  • Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs;
  • Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation will allow discernment of erythema

Key Exclusion Criteria

  • Has any visible skin disease at the application site which, in the opinion of the Investigator, will interfere with the evaluation of the test site reaction;
  • Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;
  • Is not willing to refrain from using systemic/topical anti-inflammatory analgesics such as aspirin, (occasional use of acetaminophen will be permitted);
  • Is using medication which, in the opinion of the Investigator, will interfere with the study results;
  • Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study;
  • Has psoriasis and/or active atopic dermatitis/eczema;
  • Has a known sensitivity or allergy to constituents of the materials being evaluated including diacerein, mineral oil, petrolatum, cetyl alcohol, D&C Yellow #10 and/or ethyl paraben;
  • Has damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
  • Has received treatment for any type of internal cancer within 5 years prior to study entry;
  • Has any known sensitivity to adhesives; and/or
  • Has received any investigational drug(s) within 4 weeks prior to study entry
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03472534). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search